Yesterday, Dec. 8, 2015, 78 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $727.80 to $13,173,839.00.

Highlighted Stocks Traded by Insiders:

Renasant (RNST) - FREE Research Report

Shmerling Michael D, who is Director at Renasant, bought 2,000 shares at $35.76 on Dec. 8, 2015. Following this transaction, the Director owned 149,148 shares meaning that the stake was boosted by 1.36% with the 2,000-share transaction.

The shares most recently traded at $35.38, down $0.38, or 1.07% since the insider transaction. Historical insider transactions for Renasant go as follows:

  • 4-Week # shares bought: 300
  • 4-Week # shares sold: 12,665
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 22,665
  • 24-Week # shares bought: 4,800
  • 24-Week # shares sold: 44,533

The average volume for Renasant has been 155,800 shares per day over the past 30 days. Renasant has a market cap of $1.4 billion and is part of the financial sector and banking industry. Shares are up 21.53% year-to-date as of the close of trading on Tuesday.

Renasant Corporation, through its subsidiaries, provides financial, fiduciary, and insurance services to retail and commercial customers. It operates through three segments: Community Banks, Insurance, and Wealth Management. The stock currently has a dividend yield of 1.9%. The company has a P/E ratio of 19.5. Currently, there are 3 analysts who rate Renasant a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RNST - FREE

TheStreet Quant Ratings

rates Renasant as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Renasant Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amphastar Pharmaceuticals (AMPH) - FREE Research Report

Applied Physics & Chemistry Laboratories, Inc., who is 10% Owner at Amphastar Pharmaceuticals, sold 68,117 shares at $14.71 on Dec. 8, 2015. Following this transaction, the 10% Owner owned 7.5 million shares meaning that the stake was reduced by 0.9% with the 68,117-share transaction.

The shares most recently traded at $14.19, down $0.52, or 3.66% since the insider transaction. Historical insider transactions for Amphastar Pharmaceuticals go as follows:

  • 4-Week # shares sold: 42,355
  • 12-Week # shares sold: 42,355
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 49,355

The average volume for Amphastar Pharmaceuticals has been 243,800 shares per day over the past 30 days. Amphastar Pharmaceuticals has a market cap of $654.1 million and is part of the health care sector and drugs industry. Shares are up 25.15% year-to-date as of the close of trading on Tuesday.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. Currently, there are 4 analysts who rate Amphastar Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMPH - FREE

TheStreet Quant Ratings

rates Amphastar Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins. Get the full

Amphastar Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Zogenix (ZGNX) - FREE Research Report

Tannenbaum Renee P, who is Director at Zogenix, bought 5,000 shares at $15.40 on Dec. 8, 2015. Following this transaction, the Director owned 5,000 shares meaning that the stake was boosted by 100% with the 5,000-share transaction.

The shares most recently traded at $14.14, down $1.26, or 8.91% since the insider transaction. Historical insider transactions for Zogenix go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 84,436
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 84,436
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 84,436

The average volume for Zogenix has been 398,700 shares per day over the past 30 days. Zogenix has a market cap of $347.6 million and is part of the health care sector and drugs industry. Shares are up 30.11% year-to-date as of the close of trading on Tuesday.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product includes Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. Currently, there are 4 analysts who rate Zogenix a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ZGNX - FREE

TheStreet Quant Ratings

rates Zogenix as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, poor profit margins and feeble growth in its earnings per share. Get the full

Zogenix Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.